Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial.

Guess, H A; Heyse, J F; Gormley, G J; Stoner, E; Oesterling, J E

Guess, H A; Heyse, J F; Gormley, G J; Stoner, E; Oesterling, J E.

Afiliación

Guess HA; Merck Research Laboratories, Rahway, New Jersey.

Urol Clin North Am ; 20(4): 627-36, 1993 Nov.

Article en En | MEDLINE | ID: mdl-7505970

RESUMEN

Finasteride, a 5-alpha reductase inhibitor recently introduced for the treatment of symptomatic benign prostatic hyperplasia, reduces prostate size and decreases serum PSA concentration. To interpret PSA in men treated with finasteride, it is necessary to take the reduction into account. This article describes the effect of finasteride on the serum PSA concentration in the North American Phase III clinical trial and discusses implications of these findings for the interpretation of serum PSA in men treated with finasteride.

Asunto(s)

Finasterida/uso terapéutico; Antígeno Prostático Específico/sangre; Hiperplasia Prostática/tratamiento farmacológico; Adulto; Anciano; Anciano de 80 o más Años; Método Doble Ciego; Finasterida/farmacología; Humanos; Masculino; Persona de Mediana Edad; Hiperplasia Prostática/sangre

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hiperplasia Prostática / Antígeno Prostático Específico / Finasterida Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Urol Clin North Am Año: 1993 Tipo del documento: Article Pais de publicación: Estados Unidos

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links